Leopold Ruzicka didn’t start out interested in sex hormones.
He started out interested in perfume.
More precisely, he was interested in the chemical structures of musk compounds — the base notes of countless fragrances, derived from secretions of the musk deer and other animals. Why did they smell the way they did? What was their molecular architecture? And what did that architecture have in common with other biologically active natural compounds?
These were not, on their surface, questions that would lead to a Nobel Prize in Chemistry for work on testosterone. And yet, they did. Because Ruzicka’s investigation of musk chemistry led him to a theoretical framework that turned out to be exactly right, and that applied to far more than just fragrance.
The Isoprene Rule
Ruzicka’s most important theoretical contribution was what became known as the “biogenetic isoprene rule.”
Working through the structural chemistry of terpenes — a vast family of natural compounds that includes turpentine, rubber, camphor, menthol, various plant fragrances, and, at the large end of the molecular weight spectrum, steroids and cholesterol — Ruzicka noticed a pattern.
All of these compounds, regardless of their apparent diversity, appeared to be built from the same five-carbon building block: isoprene. The terpene family, in other words, wasn’t a random collection of different molecules. It was a family tree, with all members derived from a common structural ancestor.
The implications of this insight extended to cholesterol — which, as a large terpene molecule (technically, a triterpene), was built from isoprene units assembled into its characteristic four-ring scaffold. And if cholesterol was a terpene, and terpenes could be converted into each other through chemical transformations, then perhaps cholesterol could serve as a starting material for synthesizing other members of the steroid family.
Including sex hormones.
From Basel to the Nobel Committee
Ruzicka was working at the ETH Zurich when he made his most significant contributions to terpene chemistry. He then moved to a professorship and a collaboration with the Ciba pharmaceutical company in Basel — a partnership that would prove crucial, because it gave him industrial laboratory resources and a corporate interest in the pharmacological applications of his chemistry.
In 1934, building on his theoretical framework, Ruzicka synthesized androsterone from cholesterol — successfully manipulating the cholesterol molecule to produce the androgenic steroid Butenandt had isolated from urine. This proved the concept: cholesterol could be the starting material.
In 1935, working with A. Wettstein, he went further. Using the structural knowledge of testosterone that Laqueur’s group had just published after isolating it from bull testes, Ruzicka’s team synthesized testosterone from cholesterol — publishing their results independently and within weeks of Butenandt’s identical synthesis in Göttingen.
The race was effectively a dead heat. Both teams had arrived at the same destination by slightly different chemical routes, from the same starting material — cholesterol — guided by the same understanding of steroid molecular architecture.
The Geometry of Chemistry
What made Ruzicka’s contribution distinctive was its theoretical depth. Butenandt’s approach was fundamentally empirical: extract, characterize, synthesize. Ruzicka brought a theoretical framework that connected the steroid hormones to a much broader family of natural compounds.
This mattered because it meant sex hormone chemistry wasn’t a narrow specialty. It was connected to the same molecular logic governing natural rubber, plant essential oils, and the wax coatings on leaves. Understanding one illuminated the others.
Ruzicka’s insight also had practical consequences for pharmaceutical chemistry. If cholesterol was a universal starting material for steroid synthesis, and if cholesterol was abundantly available from animal sources, then the manufacturing of steroid hormones at clinical scale was inherently feasible. You didn’t need exotic inputs. You needed chemistry.
A Complicated Nobel
Leopold Ruzicka accepted his Nobel Prize in 1939 with considerably less political drama than Butenandt — Ruzicka, who held Swiss citizenship (having emigrated from Croatia earlier in his career), was not subject to Nazi political pressure.
He was recognized jointly with Butenandt for work on sex hormones, with particular recognition of his contributions to terpene chemistry and the theoretical and practical synthesis of steroids.
After the war, Ruzicka continued his work in steroid and terpene chemistry and lived until 1976, seeing the full flowering of the pharmaceutical industry that his foundational work had helped enable. The oral contraceptive — developed in the 1950s and 1960s — was built on the same steroid chemistry he had helped systematize. So was testosterone replacement therapy. So were anabolic steroids, corticosteroids, and a range of other pharmaceutical compounds that reshape modern medicine.
The Quiet Legacy
Ruzicka is not a household name. Neither is Butenandt. But the molecules they learned to synthesize — and the framework they built for understanding how steroids work — shape the lives of hundreds of millions of people today.
Every person taking an oral contraceptive is benefiting from steroid synthesis chemistry that traces back to their work. Every man on testosterone replacement therapy. Every patient receiving corticosteroids for inflammation. Every athlete who has ever used anabolic steroids — legally or otherwise.
The chemistry is the same. Ruzicka figured out the blueprint.
What’s Next
We’ve met the chemists. We know the molecule exists, can be isolated, and can be synthesized. Now the question is: what did doctors actually do with it?
The answer, for the first thirty-five years, was: inject it. And the pharmacology of those injections — the wild peaks, the crashing troughs, the mood swings, and the very real risks — is the story of how testosterone went from Nobel discovery to clinical complication.
